This document describes a 5-year observational study to assess the long-term safety and effectiveness of etanercept (Enbrel) for the treatment of plaque psoriasis. The study will involve 2500 patients across 375 sites in the US and Canada. Patients will receive etanercept treatment determined by their physician and be evaluated every 6 months for 5 years. The primary objectives are to determine incidence rates of serious adverse events, serious infections, and malignancies. Secondary objectives include evaluating effectiveness outcomes using measures like Psoriasis Area and Severity Index. Data will be analyzed using descriptive statistics and Kaplan-Meier methodology.